{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:57:59Z","timestamp":1694660279323},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B (CHB) infection is a serious and prevalent health concern worldwide and the development of effective drugs and strategies to combat this disease is urgently needed. Currently, pegylated interferon-alpha (peg-IFN\u03b1) and nucleoside\/nucleotide analogues (NA) are the most commonly prescribed treatments. However, sustained response rates in patients remain low and the reasons are not well understood. Here, we observed that CHB patients preferentially harbored CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cells, a newly identified CD56<jats:sup>+<\/jats:sup> T cell population. Patients with this unique T cell population exhibited relatively poor responses to peg-IFN\u03b1 treatment. CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cells expressed remarkably high levels of the inhibitory molecule NKG2A as well as low levels of CD8. Even if patients were systematically treated with peg-IFN\u03b1, CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cells remained in an inhibitory state throughout treatment and exhibited suppressed antiviral function. Furthermore, peg-IFN\u03b1 treatment rapidly increased inhibitory TIM-3 expression on CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cells, which negatively correlated with IFN\u03b3 production and might have led to their dysfunction. This study identified a novel CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cell population preferentially shown in CHB patients and indicated that the presence of CD3<jats:sup>bright<\/jats:sup>CD56<jats:sup>+<\/jats:sup> T cells in CHB patients may be useful as a new indicator associated with poor therapeutic responses to peg-IFN\u03b1 treatment.<\/jats:p>","DOI":"10.1038\/srep25567","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T11:34:18Z","timestamp":1463139258000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CD3brightCD56+ T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Chuang","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"BFsrep25567_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nri1573","volume":"5","author":"B Rehermann","year":"2005","unstructured":"Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5, 215\u2013229 (2005).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep25567_CR2","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","volume":"61","author":"A Bertoletti","year":"2012","unstructured":"Bertoletti, A. & Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754\u20131764 (2012).","journal-title":"Gut"},{"key":"BFsrep25567_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","volume":"19","author":"B Rehermann","year":"2013","unstructured":"Rehermann, B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19, 859\u2013868 (2013).","journal-title":"Nat Med"},{"key":"BFsrep25567_CR4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","volume":"117","author":"MK Maini","year":"1999","unstructured":"Maini, M. K. et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117, 1386\u20131396 (1999).","journal-title":"Gastroenterology"},{"key":"BFsrep25567_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.20649","volume":"41","author":"JN Stoop","year":"2005","unstructured":"Stoop, J. N. et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771\u2013778 (2005).","journal-title":"Hepatology"},{"key":"BFsrep25567_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2011.11.030","volume":"57","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis, G. et al. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology 57, 167\u2013185 (2012).","journal-title":"Journal of Hepatology"},{"key":"BFsrep25567_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1473-3099(01)00118-9","volume":"1","author":"MF Yuen","year":"2001","unstructured":"Yuen, M. F. & Lai, C. L. Treatment of chronic hepatitis B. The Lancet. Infectious Diseases 1, 232\u2013241 (2001).","journal-title":"The Lancet. Infectious Diseases"},{"key":"BFsrep25567_CR8","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.4049\/jimmunol.163.4.2314","volume":"163","author":"DG Doherty","year":"1999","unstructured":"Doherty, D. G. et al. The human liver contains multiple populations of NK cells, T cells and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2 and Th0 cytokine secretion patterns. J Immunol 163, 2314\u20132321 (1999).","journal-title":"J Immunol"},{"key":"BFsrep25567_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0198-8859(98)00098-6","volume":"60","author":"S Norris","year":"1999","unstructured":"Norris, S. et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Valpha24-JalphaQ and gammadelta T cell receptor bearing cells. Hum Immunol 60, 20\u201331 (1999).","journal-title":"Hum Immunol"},{"key":"BFsrep25567_CR10","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.4049\/jimmunol.157.9.3886","volume":"157","author":"M Satoh","year":"1996","unstructured":"Satoh, M. et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 157, 3886\u20133892 (1996).","journal-title":"J Immunol"},{"key":"BFsrep25567_CR11","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.4049\/jimmunol.167.6.3129","volume":"167","author":"J Dunne","year":"2001","unstructured":"Dunne, J. et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 167, 3129\u20133138 (2001).","journal-title":"J Immunol"},{"key":"BFsrep25567_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0008-8749(91)90369-M","volume":"136","author":"JR Ortaldo","year":"1991","unstructured":"Ortaldo, J. R., Winkler-Pickett, R. T., Yagita, H. & Young, H. A. Comparative studies of CD3\u2212 and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement and pore-forming protein expression. Cell Immunol 136, 486\u2013495 (1991).","journal-title":"Cell Immunol"},{"key":"BFsrep25567_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/gut.2008.163600","volume":"58","author":"P Fisicaro","year":"2009","unstructured":"Fisicaro, P. et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974\u2013982 (2009).","journal-title":"Gut"},{"key":"BFsrep25567_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hep.22715","volume":"49","author":"L Ye","year":"2009","unstructured":"Ye, L. et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology 49, 753\u2013762 (2009).","journal-title":"Hepatology"},{"key":"BFsrep25567_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1189\/jlb.0312146","volume":"92","author":"W Hou","year":"2012","unstructured":"Hou, W., Ye, L. & Ho, W. Z. CD56+ T cells inhibit HIV-1 infection of macrophages. J Leukoc Biol 92, 343\u2013351 (2012).","journal-title":"J Leukoc Biol"},{"key":"BFsrep25567_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/imm.12250","volume":"142","author":"M Almehmadi","year":"2014","unstructured":"Almehmadi, M., Flanagan, B. F., Khan, N., Alomar, S. & Christmas, S. E. Increased numbers and functional activity of CD56(+) T cells in healthy cytomegalovirus positive subjects. Immunology 142, 258\u2013268 (2014).","journal-title":"Immunology"},{"key":"BFsrep25567_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1096\/fj.11-188979","volume":"26","author":"SM McAlpine","year":"2012","unstructured":"McAlpine, S. M., Issekutz, T. B. & Marshall, J. S. Virus stimulation of human mast cells results in the recruitment of CD56(+) T cells by a mechanism dependent on CCR5 ligands. FASEB J 26, 1280\u20131289 (2012).","journal-title":"FASEB J"},{"key":"BFsrep25567_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/intimm\/dxr122","volume":"24","author":"SY Al Omar","year":"2012","unstructured":"Al Omar, S. Y., Marshall, E., Middleton, D. & Christmas, S. E. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. Int Immunol 24, 409\u2013415 (2012).","journal-title":"Int Immunol"},{"key":"BFsrep25567_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.1300111","volume":"191","author":"WK Chan","year":"2013","unstructured":"Chan, W. K. et al. Multiplex and genome-wide analyses reveal distinctive properties of KIR+ and CD56+ T cells in human blood. J Immunol 191, 1625\u20131636 (2013).","journal-title":"J Immunol"},{"key":"BFsrep25567_CR20","doi-asserted-by":"publisher","first-page":"e1002594","DOI":"10.1371\/journal.ppat.1002594","volume":"8","author":"C Sun","year":"2012","unstructured":"Sun, C. et al. TGF-beta1 down-regulation of NKG2D\/DAP10 and 2B4\/SAP expression on human NK cells contributes to HBV persistence. Plos Pathog 8, e1002594 (2012).","journal-title":"Plos Pathog"},{"key":"BFsrep25567_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2012.10.039","volume":"144","author":"F Li","year":"2013","unstructured":"Li, F. et al. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology 144, 392\u2013401 (2013).","journal-title":"Gastroenterology"},{"key":"BFsrep25567_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/tan.12278","volume":"83","author":"YH Rong","year":"2014","unstructured":"Rong, Y. H. et al. Tim-3 expression on peripheral monocytes and CD3+CD16\/CD56+natural killer-like T cells in patients with chronic hepatitis B. Tissue Antigens 83, 76\u201381 (2014).","journal-title":"Tissue Antigens"},{"key":"BFsrep25567_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld, M. J. et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58, 872\u2013880 (2013).","journal-title":"Hepatology"},{"key":"BFsrep25567_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1084\/jem.189.8.1315","volume":"189","author":"LP Cousens","year":"1999","unstructured":"Cousens, L. P. et al. Two roads diverged: interferon alpha\/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med 189, 1315\u20131328 (1999).","journal-title":"J Exp Med"},{"key":"BFsrep25567_CR25","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/1521-4141(200107)31:7<2236::AID-IMMU2236>3.0.CO;2-G","volume":"31","author":"S Matikainen","year":"2001","unstructured":"Matikainen, S. et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 31, 2236\u20132245 (2001).","journal-title":"Eur J Immunol"},{"key":"BFsrep25567_CR26","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734\u20133743 (2012).","journal-title":"Blood"},{"key":"BFsrep25567_CR27","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hep.25777","volume":"56","author":"H Li","year":"2012","unstructured":"Li, H. et al. Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56, 1342\u20131351 (2012).","journal-title":"Hepatology"},{"key":"BFsrep25567_CR28","doi-asserted-by":"publisher","first-page":"9292","DOI":"10.1128\/JVI.00834-07","volume":"81","author":"L Golden-Mason","year":"2007","unstructured":"Golden-Mason, L., Castelblanco, N., O\u2019Farrelly, C. & Rosen, H. R. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol 81, 9292\u20139298 (2007).","journal-title":"J Virol"},{"key":"BFsrep25567_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.22065","volume":"47","author":"MW Fried","year":"2008","unstructured":"Fried, M. W. et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47, 428\u2013434 (2008).","journal-title":"Hepatology"},{"key":"BFsrep25567_CR30","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster, E. H. et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137, 2002\u20132009 (2009).","journal-title":"Gastroenterology"},{"key":"BFsrep25567_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jhep.2009.12.005","volume":"52","author":"Y Ju","year":"2010","unstructured":"Ju, Y. et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 52, 322\u2013329 (2010).","journal-title":"J Hepatol"},{"key":"BFsrep25567_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.201141852","volume":"42","author":"W Wu","year":"2012","unstructured":"Wu, W. et al. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol 42, 1180\u20131191 (2012).","journal-title":"Eur J Immunol"},{"key":"BFsrep25567_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/JCM.39.1.362-364.2001","volume":"39","author":"H Naito","year":"2001","unstructured":"Naito, H., Hayashi, S. & Abe, K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. Journal of Clinical Microbiology 39, 362\u2013364 (2001).","journal-title":"Journal of Clinical Microbiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep25567","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep25567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep25567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:31:04Z","timestamp":1672842664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep25567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,6]]}},"alternative-id":["BFsrep25567"],"URL":"https:\/\/doi.org\/10.1038\/srep25567","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]},"assertion":[{"value":"10 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25567"}}